Myostatin and Sarcopenia: Opportunities and Challenges - A Mini-Review
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
The progressive loss of skeletal muscle mass, strength and/or function with advancing age, termed sarcopenia, poses a major threat to independence and quality of life. Therefore, there is significant merit in better understanding the biology of sarcopenia and developing therapeutic interventions to prevent, slow or reverse its progression. Since the discovery of myostatin, a potent negative regulator of growth that is highly enriched in skeletal muscle, there has been great interest in it as a potential mediator of sarcopenia as well as a therapeutic target. The complex biology of myostatin, the promise of myostatin inhibition as an effective means to counter sarcopenia, and the challenges facing its clinical translation are reviewed herein.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Myostatin is also expressed in adipose tissue and is inversely related to insulin resistance445.”
From Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies (2018) · cites this paper as [445]
In the citing paper
“Myostatin expression increases in skeletal muscle due to obesity and IR. Thus, it could favor the loss of skeletal muscle in SO [14, 61, 62].”
From The critical role of oxidative stress in sarcopenic obesity (2021) · cites this paper as [62]
In the citing paper
“Production of myostatin, a growth-inhibiting myokine, is upregulated in sarcopenia64, whereas that of muscle-mass-stimulating irisin seems to be downregulated65.”
From Sarcopenic obesity in older adults: a clinical overview (2024) · cites this paper as [64]
Citations
Cites
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Regulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616
Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399
Myostatin Inhibits Myoblast Differentiation by Down-regulating MyoD Expression
Langley, B., Thomas, M., Bishop, A., Sharma, M., Gilmour, S., & Kambadur, R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204291200 · Cited by 908
Mosher, D. S., Quignon, P., Bustamante, C. D., Sutter, N. B., Mellersh, C. S., Parker, H. G., & Ostrander, E. A. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030079 · Cited by 826
REGULATION OF MUSCLE MASS BY MYOSTATIN
Lee, S.-J. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.012103.135836 · Cited by 819
Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size
Trendelenburg, A. U., Meyer, A., Rohner, D., Boyle, J., Hatakeyama, S., & Glass, D. J. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00105.2009 · Cited by 792
Smad2 and 3 transcription factors control muscle mass in adulthood
Sartori, R., Milan, G., Patron, M., Mammucari, C., Blaauw, B., Abraham, R., & Sandri, M. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00104.2009 · Cited by 517
Suppression of body fat accumulation in myostatin-deficient mice
McPherron, A. C., & Lee, S.-J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0213562 · Cited by 505
Inhibition of myostatin in adult mice increases skeletal muscle mass and strength
Whittemore, L.-A., Song, K., Li, X., Aghajanian, J., Davies, M., Girgenrath, S., Hill, J. J., Jalenak, M., Kelley, P., Knight, A., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02953-4 · Cited by 503
Research works printed but not linked: 1
- 10.1172/JCI13562 · doi:10.1172/jci13562 · Paper page
Cited by
Items 101–191 of 191
Zhao, Y., Liu, G., Zambito, F., Zhang, Y. J., Desilva, B. S., Kozhich, A. T., & Shen, J. X. (2017) · Analytica Chimica Acta · doi:10.1016/j.aca.2017.04.028 · Cited by 16
Increased follistatin associated with decreased gait speed among old adults
Liaw, F., Kao, T., Fang, W., Han, D., Chi, Y., & Yang, W. (2016) · European Journal of Clinical Investigation · doi:10.1111/eci.12595 · Cited by 17
Pharmacology of doping agents—mechanisms promoting muscle hypertrophy
Kristina Parr, M., Pharmaceutical and Medicinal Chemistry, I. O. P., & Müller-Schöll, A. (2018) · AIMS Molecular Science · doi:10.3934/molsci.2018.2.131 · Cited by 15
Lyssikatos, C., Wang, Z., Liu, Z., Warden, S. J., Brotto, M., & Bonewald, L. F. (2023) · Scientific Reports · doi:10.1038/s41598-023-44249-6 · Cited by 18
“An example of a negative myokine is myostatin that negatively regulates skeletal and cardiac muscle, and reduces bone mass 30,31 .”
Choi, S. J., Lee, M. S., Kang, D., Ko, G. J., Lim, H., Yu, B. C., Park, M. Y., Kim, J. K., Kim, C., Hwang, S. D., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18147344 · Cited by 18
“Considering that myostatin is mainly synthesized and secreted into circulation by skeletal muscle [6], it is conceivable that serum myostatin levels might only be a surrogate marker of muscle mass [10].”
BackgroundImpact of diets rich in olive oil, palm oil or lard on myokine expression in rats
Gauze-Gnagne, C., Raynaud, F., Djohan, Y. F., Lauret, C., Feillet‐Coudray, C., Coudray, C., Monde, A., Koffi, G., Morena-Carrere, M., Camara-Cissé, M., et al. (2020) · Food & Function · doi:10.1039/d0fo01269f · Cited by 13
Koito, Y., Yanishi, M., Kimura, Y., Tsukaguchi, H., Kinoshita, H., & Matsuda, T. (2021) · Transplantation Proceedings · doi:10.1016/j.transproceed.2021.04.021 · Cited by 16
de Oliveira, P. G. S., Schwed, J. F., Chiuso‐Minicucci, F., Duarte, S. R. D. S., Nascimento, L. M., Dorna, M. D. S., Costa, N. A., Okoshi, K., Okoshi, M. P., Azevedo, P. S., et al. (2021) · Heart Lung and Circulation · doi:10.1016/j.hlc.2021.08.018 · Cited by 12
Harish, P., Forrest, L., Herath, S., Dickson, G., Malerba, A., & Popplewell, L. J. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00184 · Cited by 12
Farkas, Z. C., Rashid, T., Chen, Y. S., Siddiqui, M. T., Yandrapalli, S., Frager, S. Z., Aronow, W. S., Bodin, R. I., & Maddineni, S. (2019) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2019.85380 · Cited by 10
“However, several reports have failed to demonstrate this correlation, and therefore we cannot use such markers to diagnose sarcopaenia [18].”
BackgroundTavoian, D., Arnold, W. D., Mort, S. C., & Lacalle, S. D. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225283 · Cited by 12
“MSTN reduction has been proposed as a potential therapeutic approach to counter several muscle wasting diseases, including sarcopenia [55], and recent investigations support this assertion.”
Michiue, K., Takayama, K., Taniguchi, A., Hayashi, Y., & Kogure, K. (2023) · Pharmaceuticals · doi:10.3390/ph16030397 · Cited by 9
Prevalence and Trends of Slow Gait Speed in the United States
Stover, E., Andrew, S., Batesole, J., Berntson, M., Carling, C., FitzSimmons, S., Hoang, T., Nauer, J., & McGrath, R. P. (2023) · Geriatrics · doi:10.3390/geriatrics8050095 · Cited by 11
“Exercise and physical activity has shown promise to be an effective treatment in slowing the process of muscle loss, and pharmaceutical therapies such as the use of myostatin inhibitors can be utilized as an additional form of treatment [35].”
BackgroundMyostatin and Activin A as Biomarkers of Sarcopenia in Inflammatory Bowel Disease Patients
Godala, M. M., Gaszyńska, E., Walczak, K., & Małecka-Wojciesko, E. (2024) · Nutrients · doi:10.3390/nu16060810 · Cited by 12
“Myostatin (MSTN), also known as growth differentiation factor 8 (GDF8), and activin A (Act A) belong to the so-called transforming growth factor-β family [32,33].”
BackgroundHirooka, M., Koizumi, Y., Tanaka, T., Nakamura, Y., Sunago, K., Yukimoto, A., Watanabe, T., Yoshida, O., Miyake, T., Tokumoto, Y., et al. (2020) · Hepatology Communications · doi:10.1002/hep4.1604 · Cited by 9
Serum Sestrin-1 Concentration Is Higher in Frail than Non-Frail Older People Living in Nursing Homes
Sanz, B., Rezola‐Pardo, C., Arrieta, H., Fraile-Bermúdez, A. B., Alonso-Puyo, J., Molano, I., Rodriguez‐Larrad, A., & Irazusta, J. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19031079 · Cited by 9
Genetics of aging and longevity
Moskalev, A., Proshkina, E., Belyi, A. A., & Solovev, I. A. (2017) · Russian Journal of Genetics Applied Research · doi:10.1134/s2079059717040074 · Cited by 10
“Artificial myostatin suppression in elderly mice improves metabolism and physical parameters (White and LeBrasseur, 2014).”
BackgroundSarcopenia and Cardiac Dysfunction
Wong, A. K., & Frishman, W. H. (2019) · Cardiology in Review · doi:10.1097/crd.0000000000000285 · Cited by 14
“Myostatin inhibition is a promising therapeutic intervention in humans because it has been shown to increase skeletal muscle mass in animal models, can be highly specific to skeletal muscle, is readily available in the circulation, and even small reductions in myostatin are expected to cause clinically relevant change…”
BackgroundWang, Q., Wang, H., Tian, H., Niu, S., & Xu, R. (2023) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s412725 · Cited by 9
“Therefore, inhibition of MSTN might serve as a treatment for sarcopenia and muscle mass loss.(20,21) The exact role of MSTN in developing frailty in the context of CHF, however, is poorly understood.”
BackgroundInfluentialSarcopenia: an Aging Perspective and Management Options
Teixeira, A. M., Nosrani, S. E., Parvani, M., Viola, J., & Mohammadi, S. (2025) · International Journal of Sports Medicine · doi:10.1055/a-2577-2577 · Cited by 10
Nutrition and Exercise Treatment of Sarcopenia in Hip Fracture Patients: Systematic Review
Yoo, J., Ha, Y., & Cha, Y. (2022) · Journal of Bone Metabolism · doi:10.11005/jbm.2022.29.2.63 · Cited by 11
“[21] The pathogenesis of sarcopenia is linked to an alteration of the homeostasis between protein anabolism and catabolism in the muscle tissue, resulting in the progressive reduction of the muscle mass.[22] This homeostasis is affected by several factors.”
BackgroundZhang, X., Ye, L., Li, X., Chen, Y., Jiang, Y., Li, W., & Wen, Y. (2021) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1747 · Cited by 10
“…a receptor for a negative regulator of skeletal muscle, myostatin, and deletion in ACVR2B causes skeletal muscle hyperplasia (an increase in the number of skeletal muscle fibers) and hypertrophy (an increase in the size of skeletal muscle fibers) (Lee & McPherron, 2001; White & LeBrasseur, 2014).”
BackgroundSung, D. K., Kim, H., Park, S. E., Lee, J., Kim, J.-A., Park, Y.-C., Jeon, H. B., Chang, J. W., & Lee, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169059 · Cited by 7
“Furthermore, myostatin inhibition has been studied in various forms of sarcopenia associated with chronic kidney disease and other chronic illnesses [37,38].”
BackgroundFascial Nomenclature: Update 2021, Part 1
Bordoni, B., Escher, A. R., Tobbi, F., Pranzitelli, A., & Pianese, L. (2021) · Cureus · doi:10.7759/cureus.13339 · Cited by 9
“To give an example, depending on the type of muscle contraction, a greater quantity of myostatin will be produced (eccentric contraction); if there is an increase in synthesized myostatin, as with advancing age and the presence of sarcopenia, this growth factor will have an anti-osteogenic effect with a worsening of v…”
BackgroundEffects of low‐dose metformin on pre‐frailty among middle‐aged and elderly pre‐diabetic people
Huang, C., Shiao, M., & Mao, T. (2022) · JCSM Rapid Communications · doi:10.1002/rco2.55 · Cited by 7
“Sarcopenia is thought to be linked to myostatin, a transforming growth factor-β that causes muscle protein degradation leading to inhibition of muscle growth.(2,3)”
BackgroundNovel insights regarding mechanisms for treatment of sarcopenia
Kraemer, R. R., & Castracane, V. D. (2014) · Metabolism · doi:10.1016/j.metabol.2014.11.002 · Cited by 8
Myostatin-driven muscle hypertrophy: a double-edged sword in muscle physiology
Dewasi, G., Nagda, P., Bahl, G., Jain, V., & Gupta, S. K. (2025) · Journal of Rare Diseases · doi:10.1007/s44162-025-00086-x · Cited by 14
“Animal studies (sheep, cattle, mice) demonstrate that myostatin mutations lead to larger muscle myofibers and increased myofiber numbers [48, 53–56].”
Shaikh, S., Ahmad, K., Lim, J. H., Ahmad, S. S., Lee, E. J., & Choi, I. (2025) · Pharmaceuticals · doi:10.3390/ph18091407 · Cited by 8
“In older individuals, elevated MSTN protein and mRNA levels are linked to reduced fat-free mass [104], implying that MSTN plays a role in sarcopenia development [105].”
Sarcopenia in Aging: Pathogenesis, Diagnosis, and Emerging Therapeutic Frontiers
Jeyaraman, M., Jeyaraman, N., Nallakumarasamy, A., Ramasubramanian, S., Muthu, S., Murugan, S., Rajendran, S. N. S., Rajendran, R. L., Ahn, B., & Gangadaran, P. (2025) · Molecular Imaging and Biology · doi:10.1007/s11307-025-02071-8 · Cited by 10
2′-Fucosyllactose improved muscle health in middle-aged mice performing forced swimming exercise
Kim, J. K., Shin, C. S., Yoon, J.-W., Jeon, S.-M., Bang, J., Ku, S., & Jegal, K. H. (2024) · Journal of Functional Foods · doi:10.1016/j.jff.2024.106567 · Cited by 5
Lu, L., He, X., Ma, L., Liu, Y., & Chen, N. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.905460 · Cited by 8
“, myostatin [MSTN] (White and LeBrasseur, 2014) and follistatin [FST] (Echeverria et al.”
BackgroundTanaka, Y., Aoyagi, K., UMETANI, Y., TANAKA, Y., Kaku, H., Minami, T., Isobe, T., Murakami, N., Fujita, F., & Akagi, Y. (2023) · Anticancer Research · doi:10.21873/anticanres.16563 · Cited by 5
Altajar, S., Wang, N., Rosenthaler, M. P., Murabito, J. M., & Long, M. T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12247523 · Cited by 7
Protective effect of myostatin gene deletion on aging-related muscle metabolic decline
Chabi, B., Pauly, M., Carillon, J., Carnac, G., Favier, F. B., Fouret, G., Bonafos, B., Vanterpool, F., Vernus, B., Coudray, C., et al. (2016) · Experimental Gerontology · doi:10.1016/j.exger.2016.01.016 · Cited by 6
Genetics of aging and longevity
Moskalev, A., Proshkina, E., Belyi, A. A., & Solovev, I. A. (2016) · Vavilov Journal of Genetics and Breeding · doi:10.18699/vj16.171 · Cited by 8
Mo, C.-L., Wang, Z.-Y., Bonewald, L., & Brotto, M. (2017) · Molecular and integrative toxicology · doi:10.1007/978-3-319-56192-9_9
Anuja, A. K., Bhadu, D., Naveen, R., Singh, M. K., Rai, M. K., Agarwal, V., & Gupta, L. (2021) · Indian Journal of Rheumatology · doi:10.4103/injr.injr_309_20 · Cited by 5
“[3,23] These muscle regeneration pathways have potential and can act as a window of opportunity to intervene with pathways specific inhibition.”
Sarkopenia pada Lansia: Problem Diagnosis dan Tatalaksana
Sanglah, R., & Aryana, I. G. P. S. (2021) · Baswara Press eBooks · doi:10.53638/9786239795580 · Cited by 13
State-of-the-art insights into myokines as biomarkers of sarcopenia: a literature review
Moussaoui, O. R., Deligiannis, I., Petrov, P.-P. S., Velikova, T. V., & Assyov, Y. S. (2025) · International Journal of Physiology Pathophysiology and Pharmacology · doi:10.62347/rneq8696 · Cited by 4
Kurose, S., Onishi, K., Miyauchi, T., Takahashi, K., & Kimura, Y. (2023) · Endocrine Research · doi:10.1080/07435800.2023.2253452 · Cited by 4
Insight on sarcopenic obesity and epicatechin as a promising treatment option
Sabarathinam, S., Dhanasekaran, D., & Ganamurali, N. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102856 · Cited by 7
Physical Activity, Body Composition, Serum Myokines and the Risk of Death in Hemodialysis Patients
Koźma-Śmiechowicz, M. A., Gajewski, B., Fortak, P., Gajewska, K., & Nowicki, M. P. (2023) · Medicina · doi:10.3390/medicina59112020 · Cited by 4
“Myostatin adversely affects the proliferation and differentiation of skeletal muscle cells, limiting their growth through its regulatory effect on translational pathways [14].”
BackgroundLee, E. J., Shaikh, S., Lee, J. H., Hur, S. J., & Choi, I. (2025) · Scientific Reports · doi:10.1038/s41598-025-98386-1 · Cited by 5
“The inhibition of MSTN activity in MSCs to promote myogenesis has been investigated, thus potentially contributing to the long-term treatment of muscle-wasting diseases, such as sarcopenia and cachexia 17–19 .”
Geneand cell-based therapy of muscle system hereditary disorders: state-of-art
Deev, R. V., Мавликеев, М. О., Bozo, I. Y., Pulin, A. A., & Eremin, I. I. (2014) · Genes and Cells · doi:10.23868/gc120368 · Cited by 5
Nguyen, T. V., Tran, K. D., Bui, K. X., Le, D., & Nguyen, T. N. (2020) · Australian Journal on Ageing · doi:10.1111/ajag.12789 · Cited by 4
Faria, I. A., da Mata, D. L., Lima, A. C. D. S., Belo, M. C. P. E., de Almeida, G. C., & Brasil, A. R. D. C. (2026) · Revista Multidisciplinar do Nordeste Mineiro · doi:10.66104/0p39n076 · Cited by 5
Aryana, I. G. P. S., Astika, I. N., Kuswardhani, R. A. T., Putrawan, I. B. P., Purnami, N. K. R., Semaradana, W. G. P., Lestari, A. A. W., & Wande, I. N. (2019) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v11i3.822 · Cited by 4
“Deletion and loss of function of myostatin causes skeletal muscle hyperplasia and hypertrophy.(6) Therefore the researchers intend to examine the relationship of myostatin with sarcopenia in elderly.”
BackgroundInfluentialKanodia, A. K., & Noland, D. (2020) · Springer eBooks · doi:10.1007/978-3-030-30730-1_46 · Cited by 3
Koo, G., Kwon, H. O., Kim, J., Lee, S. H., Shim, S. L., & Jang, K. H. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46100664 · Cited by 3
“Myostatin, a negative regulator of muscle growth, inhibits muscle protein synthesis via suppressing the Akt signaling [17].”
BackgroundCornet, S., Quinonez, K., Warling, X., Jouret, F., Lanot, A., Bruyère, O., Cavalier, E., & Delanaye, P. (2025) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2025.01.005 · Cited by 3
Lyssikatos, C., Wang, Z., Liu, Z., Warden, S. J., Brotto, M. A. P., & Bonewald, L. F. (2023) · Research Square · doi:10.21203/rs.3.rs-2492688/v1 · Cited by 3
Biomarkers of Sarcopenia: Current Status and Future Perspectives
Luo, B., Li, W., Zhang, Y., Liu, M. H., Zhang, K., Huang, S., & He, P. (2026) · Aging Medicine · doi:10.1002/agm2.70088 · Cited by 3
The hallmarks of skeletal muscle health
Vainshtein, A., Blaauw, B., Bock, K. D., Muñoz‐Cánoves, P., Olson, E. N., Ottenheijm, C. A. C., Richter, E. A., Ruas, J. L., Schaeffer, L., Spiegelman, B. M., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01595-9 · Cited by 6
“Chronic myostatin signalling contributes to catabolic states such as sarcopenia and cachexia, while its inhibition promoted gains in lean mass and bone 146,278,279 .”
Пальцын, А. А. (2018) · Zhurnal «Patologicheskaia fiziologiia i eksperimental`naia terapiia» · doi:10.25557/0031-2991.2018.02.113-121 · Cited by 2
Appendicular lean mass in women with rheumatoid arthritis: Focus on immunological markers
Dobrovolskaya, O. V., Demin, N. V., Feklistov, А. Y., Diatroptov, M. E., Samarkina, E. Y., & Toroptsova, N. V. (2024) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2024-529-534 · Cited by 2
Sarkopenie und Frailty 2016: Auf getrennten Wegen
Bauer, J. M. (2016) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-016-1137-7 · Cited by 2
Oliver, C. E., Carter, J. L., Hong, J. S., Xu, M., Kraus, W. E., Huffman, K. M., & Truskey, G. A. (2025) · Communications Biology · doi:10.1038/s42003-025-07970-8 · Cited by 2
“…Lastly, RNA-Seq results should be verified with the quantification of selected gene sets, especially for the statement ‘Pim1 and MT-1 were identified as potential therapeutic targets for treating RA-associated muscle dysfunction’.”
Sun, Y.-X., Li, Z. H., Jie, Y., Yang, N., Yin, Z., & Hou, Z. (2026) · Communications Biology · doi:10.1038/s42003-026-09665-0 · Cited by 2
Chu, R., Li, M., Zhu, C., Du, Y., Xie, Y., Ni, T., & Wu, S. (2026) · BMC Sports Science Medicine and Rehabilitation · doi:10.1186/s13102-026-01655-3 · Cited by 2
“…frailty: studies have found that serum MSTN levels in sarcopenia patients are significantly higher than those in healthy controls; [17] a study on Chinese patients with chronic kidney disease also confirmed that serum MSTN levels are significantly correlated with the severity of muscle loss [18].”
Enfermedad ósea de Paget, osteomalacia y sarcopenia
Montes, J. D. P., Corral-Gudino, L., Sánchez, M. D., Calero, I., Carranco, T., & Quesada-Moreno, A. (2014) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(14)70814-5 · Cited by 1
Gene therapy approaches to the duchenne muscular dystrophy theatment
Zaynitdinova, M. I., Smirnikhina, S. A., Lavrov, A. V., Eremin, I. I., & Pulin, A. A. (2019) · Genes and Cells · doi:10.23868/201912026 · Cited by 4
Anabole und molekulare Interventionen am Muskel: Sinnvolle Anti-Aging-Strategie?
Münzer, T. (2017) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-017-1299-y · Cited by 1
Silva, J. C., Tavares, P., Ferreira, R. M., Santos, L. L., & Monteiro, E. F. (2021) · International Journal of Otolaryngology and Head & Neck Surgery · doi:10.4236/ijohns.2021.104029 · Cited by 1
Han, M., Song, S. H., Kim, S. H., Cha, R., Kang, S. H., An, W. S., & Kim, J. C. (2023) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.22.143 · Cited by 2
“The abundance of myostatin does not exhibit any clear activity; and the level of myostatin depends on many factors, such as growth of skeletal muscle mass, aging, weight loss, or kidney function [27].”
ÇELİK, G. E., Aksakal, S. E., & Üstün, Y. E. (2024) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.55730/1300-0144.5867 · Cited by 2
“It also plays a role in muscle-wasting conditions, being seen at lower concentrations in patients with sarcopenia [8].”
BackgroundMiedany, Y. M. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-87950-1_3 · Cited by 1
Khanna, V. (2017) · Orthopedics and Rheumatology Open Access Journal · doi:10.19080/oroaj.2017.05.555655 · Cited by 1
Miedany, Y. M. E., Naby, M. M. H. E., Abu-Zaid, M. H., Mahran, S., Eissa, M., Saber, H. G., Tabra, S. A. A., Ibrahim, R. A., Galal, S., & Elwakil, W. (2023) · Egyptian Rheumatology and Rehabilitation · doi:10.1186/s43166-023-00173-1 · Cited by 1
Effects of 10 Weeks of Periodized Resistance Training on Sarcopenia Classification in Older Women
Slezak, S. G. (2017) · Digital Commons - URI (University of Rhode Island) · doi:10.23860/thesis-slezak-samuel-2017
Antikörper als Therapieoption bei geriatrischen Patienten
Gosch, M., & Wicklein, S. (2017) · Zeitschrift für Gerontologie und Geriatrie · doi:10.1007/s00391-017-1352-x
Iolascon, G., Moretti, A., Stefano, L., & Gimigliano, F. (2018) · Contemporary Endocrinology · doi:10.1007/978-3-319-73742-3_11
Lobo, D. M. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2018.tde-15032018-100220
Sarcopenic Obesity in the Elderly
Naafs, M. A. (2018) · Journal of Physical Fitness Medicine & Treatment in Sports · doi:10.19080/jpfmts.2018.05.555675
“Myostatin (growth differentiation factor 8) inhibits muscle cell growth and differentiation and could be a potential mediator of sarcopenia [17].”
BackgroundFrom brain to muscle and back : novel approaches to harness the benefits of exercise
Kelahmetoglu, Y. (2020) · Figshare
Crocco, P., Iannone, F., Dato, S., Rose, G., & Passarino, G. (2021) · Elsevier eBooks · doi:10.1016/c2019-0-04856-x · Cited by 1
Recarey-Rodríguez, A. E. (2021) · Academica-e (Universidad Pública de Navarra) · doi:10.48035/tesis/2454/39685 · Cited by 1
Maslova, O., Koliada, A. K., & Vaiserman, A. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11292-9 · Cited by 1
Different components of frailty in the aging subjects—The role of sarcopenia
Crocco, P., Dato, S., Iannone, F., Passarino, G., & Rose, G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822569-1.00011-1
MYOSTATIN AS A POTENTIAL DIAGNOSTIC BIOMARKER IN ELDERLY PATIENTS WITH SARCOPENIA
Saad, M. A., Ahmed, S., Abdelmajeed, M., Elwafa, R. A., & Emara, R. H. (2024) · NILES Journal forGeriatric and Gerontology/NILES Journal for Geriatric and Gerontology · doi:10.21608/niles.2024.275569.1081 · Cited by 1
“Myostatin is a myokine, and a potent negative regulator of growth that is highly enriched in the skeletal muscle, there has been great interest in it as a potential mediator of Sarcopenia (16) .”
BackgroundThe role of genes and myokines of developing sarcopenia: A review
Valeeva, F. V., Rodygina, Z. A., & Yilmaz, T. S. (2024) · Consilium Medicum · doi:10.26442/20751753.2024.4.202735 · Cited by 1
Kimura, T., Tamaki, S., Yamada, T., Watanabe, T., Fukunami, M., Yasumura, Y., Nakagawa, A., Nakagawa, Y., Yano, M., Hayashi, T., et al. (2025) · International Heart Journal · doi:10.1536/ihj.24-475
Asadpour, S. M., Daryanoosh, F., & Zarifkar, A. H. (2025) · Biogerontology · doi:10.1007/s10522-025-10363-3
“It can be accepted that the abundance of internal inhibitors of myostatin or the degree to which they interact with myostatin is independently affected by aging (White and LeBrasseur 2014).”
Cellular and Molecular Mechanisms Underlying Congenital Myopathy-related Weakness
Lindqvist, J. (2014) · DiVA (Digitala Vetenskapliga Arkivet)
Fleming, K., & Whitehouse, W. H. (2026) · Veterinary Sciences · doi:10.3390/vetsci13010089
“GDF8 favors muscle breakdown through activation of the ubiquitin-proteasome pathway, inhibition of satellite muscle cell recruitment, and inhibition of protein synthesis through suppression of the anabolic Akt/mechanistic target of rapamycin signaling pathway [4,25,26].”
Sarcopenia: effects of Robuvit® supplementation on loss of muscular mass and strength
Belcaro, G. V., Cesarone, M. R., Dugall, M., Bavera, P. M., Ledda, A. G., SCIPIONE, C., SCIPIONE, V., Corsi, M., David, C. O. X., Hosoi, M., et al. (2026) · Minerva Medica · doi:10.23736/s0026-4806.25.09735-6
Mallard, J. (2022) · theses.fr (ABES) · doi:10.70675/f8b2c96bzc4cdz4249z8e59z5f87c7ca2462
Xing, Y., He, X., Song, Y., & Chen, N. (2026) · BMC Geriatrics · doi:10.1186/s12877-026-07464-0
“Sarcopenia is widely associated with myo-kines and characterised by high levels of myostatin [17], which can exacerbate swallow-related muscle weakness, eventually contributing to sarcopenic dysphagia [18, 19].”
Habibi, K., Setiawan, H. K., Qurnianingsih, E., Purba, A. K. R., Darmawan, R., & Nahar, A. M. (2026) · Biomolecular and Health Science Journal · doi:10.4103/bhsj.bhsj_15_26
Frigerio, F., & Donini, L. M. (2026) · Endocrinology · doi:10.1007/978-3-030-71067-5_23-1
Sukocheva, O. A., Harding, D., Ow, T., & Tse, E. (2026) · Biomedicines · doi:10.3390/biomedicines14092082 · Cited by 1
“Myostatin inhibition strategies include the use of ActRIIB ligand traps, myostatin-neutralising antibodies, and myostatin propeptides [133] (summarised in Table 3).”
Metadata
- Authors
- White, T. A., & LeBrasseur, N. K.
- Affiliations
- Mayo Clinic (US)
- Venue
- Gerontology
- Publisher
- S. Karger AG
- Published
- 2014
- Volume
- 60
- Issue
- 4
- Pages
- 289-293
- ISSN
- 0304-324X (ISSN-L)
- 1423-0003
- OpenAlex
- W2006774297
- Cited by
- 191
- References
- 32
- Citations by year
- 2026: 11 · 2025: 12 · 2024: 14 · 2023: 23 · 2022: 17 · 2021: 25 · 2020: 17 · 2019: 16 · 2018: 12 · 2017: 13 · 2016: 14 · 2015: 7 · 2014: 10
- FWCI
- 1.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Gerontology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Mayo Clinic
- Center for Cell Signaling in Gastroenterology, Mayo Clinic
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK084567)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- myostatin, sarcopenia, skeletal muscle atrophy, muscle strength, aging, myostatin inhibition, therapeutic target, clinical translation, muscle growth regulation
- MeSH terms
- Aged, Aging, Animals, Humans, Signal Transduction, Muscle, Skeletal, Mice, Myostatin, Sarcopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.